Checkpoint Inhibitors and the Gut

Abstract

Checkpoint inhibitors have revolutionized treatments in modern oncology, including many conditions previously relegated to palliative therapies only. However, emerging recognition of checkpoint inhibitor-related adverse events has complicated the status of checkpoint inhibitor-related therapies. This review article discusses gastrointestinal adverse events as a result of checkpoint inhibitor therapy, as well as limitations of current guidelines, thus providing recommendations for guideline revision and future study direction.

Keywords

• inflammatory bowel
• oncology
• PDL-1
• CTLA-4
• cancer
• checkpoint inhibitor